Literature DB >> 10787031

Characterization of chromosome 17 abnormalities in medulloblastomas.

N Aldosari1, B K Rasheed, R E McLendon, H S Friedman, D D Bigner, S H Bigner.   

Abstract

Loss of portions of chromosome 17p, usually through the formation of i(17qp) is a well-known finding in medulloblastomas. Loss of heterozygosity (LOH) studies, however, occasionally demonstrate loss of the more distal portions of 17p, a pattern which is more consistent with a terminal deletion. Here we use a combination of routine karyotyping, fluorescence in situ hybridization (FISH) and LOH studies on four medulloblastoma cell lines and one xenograft to demonstrate the spectrum of chromosome 17 abnormalities which occur in these tumors. Cell line D-556 Med showed a typical dicentric i(17q) and cell line D-721 Med showed two normal copies of chromosome 17 by all methods. Cell line D-425 Med showed loss of terminal 17p by LOH, while the karyotype showed what appeared to be an i(17q). FISH and chromosome 17 painting, however, demonstrated that the abnormal chromosome 17 was actually formed through an unbalanced translocation involving two copies of chromosome 17, with breakpoints at p12 and q11-1, an explanation which reconciled the cytogenetic and LOH findings. Cell line D 581 Med had a terminal deletion at 17p11.2. The finding of two cells with i(17q) in this case by interphase FISH suggests that the terminal deletion arose from breakage of an i(17q). Finally, xenograft D 690 Med showed LOH for regions distal to 17p12, whereas karyotyping, FISH using probes on 17p, and chromosome 17 painting showed two intact copies of chromosome 17. This pattern can be explained by homologous recombination. These data support the concept that the critical deletion of 17p can occur through a variety of mechanisms in the medulloblastoma. The losses may occur through typical i(17q), as well as other mechanisms such as terminal deletions, possibly through breakage of i(17q), unbalanced translocations and homologous recombination.

Entities:  

Mesh:

Year:  2000        PMID: 10787031     DOI: 10.1007/s004010051134

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  6 in total

1.  Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells.

Authors:  Wolfgang Hartmann; Arend Koch; Hendrik Brune; Anke Waha; Ulrich Schüller; Indra Dani; Dorota Denkhaus; Wilhelma Langmann; Udo Bode; Otmar D Wiestler; Karl Schilling; Torsten Pietsch
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

2.  Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.

Authors:  Ae Kyung Park; Seung-Jun Lee; Ji Hoon Phi; Kyu-Chang Wang; Dong Gyu Kim; Byung-Kyu Cho; Christine Haberler; Sarah Fattet; Christelle Dufour; Stéphanie Puget; Christian Sainte-Rose; Franck Bourdeaut; Jacques Grill; Olivier Delattre; Seung-Ki Kim; Woong-Yang Park
Journal:  Neuro Oncol       Date:  2011-11-16       Impact factor: 12.300

3.  Interchromosomal crossover in human cells is associated with long gene conversion tracts.

Authors:  Efrem A H Neuwirth; Masamitsu Honma; Andrew J Grosovsky
Journal:  Mol Cell Biol       Date:  2007-05-21       Impact factor: 4.272

Review 4.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

Review 5.  Analysis of chromosome 17 miRNAs and their importance in medulloblastomas.

Authors:  Sebastian López-Ochoa; Marina Ramírez-García; Eduardo Castro-Sierra; Francisco Arenas-Huertero
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

6.  A statin-regulated microRNA represses human c-Myc expression and function.

Authors:  Apana A L Takwi; Yan Li; Lindsey E Becker Buscaglia; Jingwen Zhang; Saibyasachi Choudhury; Ae Kyung Park; Mofang Liu; Ken H Young; Woong-Yang Park; Robert C G Martin; Yong Li
Journal:  EMBO Mol Med       Date:  2012-08-07       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.